Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.
ST Herbst 2022 der DGNC
Programm
Personen
Suche
EN
Alle Personen
Anna-Laura Potthoff
Bonn
Universitätsklinikum Bonn
Sortiert nach Typ
Datum
Vortrag
27.10.2022
11:20
–
11:30
7 Min.
3 Min.
Abstractvortrag
Brain metastasis as first manifestation versus long-term consequence of primary cancer – does time of diagnosis matter?
27.10.2022
11:50
–
12:00
7 Min.
3 Min.
Abstractvortrag
Survival in patients with surgically treated brain metastases: does infratentorial location matter?
27.10.2022
12:00
–
12:10
7 Min.
3 Min.
Abstractvortrag
Benchmarking of safety indicators for surgical treatment of brain metastases combined with intraoperative radiotherapy: results of a prospective observational study with comparative matched-pair analysis
27.10.2022
15:05
–
15:15
7 Min.
3 Min.
Abstractvortrag
Drug repurposing of tonabersat as a potent gap junction inhibitor sensitizes primary glioblastoma cells for temozolomide
29.10.2022
09:50
–
10:00
7 Min.
3 Min.
Abstractvortrag
Pathologic bone mineral density in patients with surgically treated brain metastasis from lung cancer (NSCLC): implications of an unrecognized prognostic factor
Weitere Beteiligungen
27.10.2022
11:20
–
11:30
7 Min.
3 Min.
Abstractvortrag
Brain metastasis as first manifestation versus long-term consequence of primary cancer – does time of diagnosis matter?
27.10.2022
11:30
–
11:40
7 Min.
3 Min.
Abstractvortrag
Repurposing the SHORT-score: Prediction of short-term mortality in surgically treated brain metastases
27.10.2022
11:40
–
11:50
7 Min.
3 Min.
Abstractvortrag
Prognostic implications of unplanned readmission to the intensive care unit following surgery for brain metastasis
27.10.2022
11:50
–
12:00
7 Min.
3 Min.
Abstractvortrag
Survival in patients with surgically treated brain metastases: does infratentorial location matter?
27.10.2022
12:00
–
12:10
7 Min.
3 Min.
Abstractvortrag
Benchmarking of safety indicators for surgical treatment of brain metastases combined with intraoperative radiotherapy: results of a prospective observational study with comparative matched-pair analysis
27.10.2022
15:05
–
15:15
7 Min.
3 Min.
Abstractvortrag
Drug repurposing of tonabersat as a potent gap junction inhibitor sensitizes primary glioblastoma cells for temozolomide
27.10.2022
15:15
–
15:25
7 Min.
3 Min.
Abstractvortrag
Inhibition of intercellular communication via gap junctions renders medulloblastoma cells more susceptible for cytotoxic therapy
27.10.2022
15:25
–
15:35
7 Min.
3 Min.
Abstractvortrag
The Alcatraz-Strategy: A novel multimodal therapeutic approach for glioblastoma
28.10.2022
11:55
–
12:05
7 Min.
3 Min.
Abstractvortrag
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy – the MecMeth/NOA-24 trial study protocol
28.10.2022
15:55
–
16:05
7 Min.
3 Min.
Abstractvortrag
Preoperative MRI shape analysis as a tool for safety profile assessment in surgery for intracranial meningioma
29.10.2022
09:10
–
09:20
7 Min.
3 Min.
Abstractvortrag
Prognostic impact of obesity in newly-diagnosed glioblastoma: A secondary analysis of CeTeG/NOA-09 and GLARIUS
29.10.2022
09:50
–
10:00
7 Min.
3 Min.
Abstractvortrag
Pathologic bone mineral density in patients with surgically treated brain metastasis from lung cancer (NSCLC): implications of an unrecognized prognostic factor
© Conventus Congressmanagement & Marketing GmbH
Impressum
Datenschutz